"Yeah mate, see smoke only...and smell shite ...every year same reply In 3 years didn't hear any updates or progress about research we payed 3 mln...not a bad income of 1 mln every year...and we don't know exactly where money go...Pay again? Or search another "perfect" deal..."
Mr D, this might help you understand how the MS research in Israel that MCRG is doing is going, this announcement was from the 2 March so its pretty current. Sorry if you missed the previous MCRG updates in recent years.
research and innovation cannabis extract as a potential therapy for multiple sclerosis Millions of people worldwide are afflicted with multiple sclerosis (MS) (Compston & Coles, 2008). MS is a chronic disease of the brain and spinal cord and is a common cause of serious physical disability in young adults, especially women (Compston & Coles, 2008). MS has a heterogeneous presentation that can include sensory and visual disturbances, motor impairments, fatigue, pain and cognitive deficits.Five new skilled researchers have joined the team at the cannabis research laboratory at the Technion in Haifa, Israel, led by Professor David Meiri who is the principal investigator of this work, and the head of immunology group Dr Hila Novak Kotzer, and the head of the neurology group Dr Gil Lewitus.The overall objective of the study is to match effective Cannabis extracts that regulate/modulate immune function, specifically, autoimmunity in MS in order to optimise treatment for MS patients. In the last year, the scientific team at Technion has established the novel ability to analyse the specific chemical composition of Cannabis plants. The purpose was to identify the effects of different cannabinoids and terpenes both individually and in combination on the function of immune cells, specifically on MS-derived autoimmune and regulatory cells in vitro. The evaluation of the immunomodulatory properties of specific cannabinoid extracts, in vivo rodent models of MS, allows them to detect the most effective Cannabis extract and cannabinoid profiles for regulating immunopathology in MS.The 1st step was to characterise clinically-used Cannabis chemovars. They started by analysing different cannabis chemovars that are anticipated to have an effect on the immune system.The 2nd step was to screen for the immunoregulatory properties of different Cannabis chemovars on different immune cell function and MS immunopathology. For this purpose, the Technion team established an in-vitro screening system for various immune cells that play a central role in both mediating and regulating MS pathophysiology. This means that cannabinoids that can regulate these cells functions have a high therapeutic potential. It was noted that not all chemovars have the same killing properties.The 3rd step, following the findings that different Cannabis chemovars had different killing abilities, was to test the effect of different Cannabis chemovars on specific proliferating human cells. It is anticipated that harvesting the potential of cannabinoids as part of the arsenal for MS therapy may open new treatment possibilities for the immunopathology in MS. From the screening of different Cannabis extracts on specific human cells, the 4th step was to test the killing properties of Cannabis extracts.The next stage in Technion’s research was to demonstrate the neuroprotective properties of specific Cannabis extracts on MS rodent models. In the last year the team finished establishing an acute rodent model for MS in lab. These exciting and promising results showed that some specific cannabis formulations appear to have a great potential to improve symptoms. Human trials on the specific identified formulations are currently being undertaken, patents are currently being applied for, and it may be possible for a cannabis product to be available for development and production later this year. The Board are extremely pleased at the success to date of this research and of the humanitarian and commercial benefits that this may translate into for so many people and for the shareholders of CGB.
CGB Price at posting:
0.9¢ Sentiment: Hold Disclosure: Held
